evaluate the food technology company chinova bioworks on glp-1 diet Drugs Are Rewriting Rules of Impact of GLP-1 Weight Loss

PMID: 27983438

Linking temperature, cation concentration and water activity for the B to Z conformational transition in DNA

Potential Downsides and Unknowns Long-term safety : Retatrutide is still in trials, so long-term LDL and cardiovascular outcomes arent confirmed

New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025

Biotechniques 50 , 98115 (2011)

M.FitchettD.Von EynattenM.MattheusM.et al